Salix Pharmaceuticals, Ltd. SLXP today announced that as of May
30, 2013, it had purchased from Olon S.p.A. (formerly Solmag) a pending
patent application claiming amorphous rifaximin and an issued patent
that Olon recently acquired from Apotex Pharmachem, Inc. claiming
amorphous rifaximin, together with related intellectual property rights.
Additionally, Olon granted Salix the exclusive worldwide right under
Olon's intellectual property rights to exploit amorphous rifaximin.
About XIFAXAN® (rifaximin) 550 mg tablets
Indication for XIFAXAN® 550 mg
XIFAXAN 550 mg is a rifamycin antibacterial indicated for reduction in
risk of overt hepatic encephalopathy (HE) recurrence in patients ≥ 18
years of
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in